Last reviewed · How we verify
A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Groups Efficacy and Safety Extension Study of MK0928 in the Treatment of Adult Outpatients With Primary Insomnia
The purpose of this trial is to study the safety and effectiveness of MK0928 for adults with insomnia.
Details
| Lead sponsor | H. Lundbeck A/S |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 600 |
| Start date | 2004-10 |
| Completion | 2007-02 |
Conditions
- Insomnia
Interventions
- MK0928, gaboxadol / Duration of Treatment - 1 year
- Comparator: placebo / Duration of Treatment -1 year
Primary outcomes
- Patient-reported amount of sleep and time to fall sleep at night after three months